Preventive Cardiology Digest

Risk Assessment Refinements

• PREVENT Markers in Older Adults: Post hoc ASPREE analysis found lowest quartile polygenic risk for coronary artery...

• In adults ≥70 years at intermediate PREVENT-estimated ASCVD risk, lowest-quartile polygenic risk for coronary artery disease provided the strongest...

• South Asians face approximately two-fold higher ASCVD risk versus White Caucasians, with pronounced excess in coronary heart disease and MI.
  -...

A new editorial synthesizes 2025 cardiovascular trials, emphasizing precision-guided strategies to tackle residual cardiovascular risks after standard therapy. This framing points to evolving directions in preventive cardiology research and practice.

Inclisiran produced ~50% LDL cholesterol reduction from baseline at day 510 across all eGFR groups down to 15 ml/min/1.73 m², with sustained...

Hypertension Outcomes Research

• 🔥 SPRINT Secondary Analysis: Metabolic health status in treated hypertension patients from SPRINT does not...

• PREVENT score plus enhancers (CKD, frailty) enable individualized primary prevention decisions beyond age alone.
• Moderate-intensity statins cut...

Metabolically unhealthy hypertension patients without diabetes or CVD face a 27% higher risk of major cardiovascular events versus metabolically...

Lipid Management Evidence

• 🔥 Safety of very low LDL-cholesterol: Review addresses ten common concerns with genetic and RCT evidence showing...

A new course titled A Clinical Compass in High Risk Primary Prevention offers guidance for high-risk patients.

Pregnancy complications signal elevated long-term cardiovascular risk, making the postpartum period a critical window for prevention.

• Pregnancy is...

Cancer patients show markedly higher predicted heart age (65.88 vs 54.20 years) and excess heart age than those without cancer, driven by shared risk...

Very low LDL-C delivers proportional ASCVD risk reduction with no consistent signals of harm in cognition, cancer, stroke, cataracts or hormones. Only...

Novel Lipid Pathways

• 🔥 CTSA Inhibition for Cholesterol: New mechanism shows cathepsin A inhibition stabilizes LDL receptors via Ral protein...

A Ral-dependent pathway activated by dietary cholesterol depletes liver LDL receptors via cathepsin A (CTSA), revealing a mechanism distinct from...

Dr. Filipe Moura's new Yale lab and cross-specialty working group demonstrate why breaking traditional silos is essential for cardiometabolic...

In type 2 diabetes patients aged ≥75 years, statin initiation cut CVD incidence by 31% (HR 0.69) and all-cause mortality by 35% (HR 0.65), with...

GLP-1 medications deliver cardiovascular benefits for women beyond weight loss, particularly as heart disease risk rises during menopause. They lower...

New Therapeutic Options

• 🔥 Orforglipron Phase 3 Results: Eli Lilly's oral GLP-1 orforglipron showed 12.4% average weight loss in Phase 3 trials...

Regulatory Updates

• 🔥 Diazyme Lp(a) Assay Clearance: FDA granted 510(k) clearance June 18, 2026 for Diazyme’s isoform-independent Lp(a) molarity...